Patti Payne: AML survivor returns home after bone marrow transplant, grateful for milestones

What ’s on your gratitude list for Thanksgiving and into the holidays? In the face of life-threatening challenges Ryan Dwyer, 40, is grateful for a long list of things. Gratitude is at the very fiber of his being. This Kenmore man just underwent a bone marrow transplant for acute myeloid leukemia — his second round of this aggressive disease. He thought he beat it the first time, but learned in mid-2020 it had returned with a vengeance, and thus the more drastic treatment was needed. Dwyer…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Graft-versus-host disease (GVHD) is a major complication of bone marrow transplantation. Polymyositis with myonecrosis is a rare manifestation of GVHD. Here, we report the case of a 32-year-old man with acute myeloid leukemia who developed GVHD after transplant. He subsequently developed polymyositis, which was diagnosed on PET/CT and confirmed on pathology. Treatment with corticosteroids resulted in the resolution of the symptoms. Abnormal muscular FDG uptake resolved on the follow-up PET/CT.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
We examined 100 patients in the bone marrow transplantation department. Of the 100 patients, 61 (61%) men and 39 (39%) women with a median age of 39 years. The most frequent underlying diseases were acute lymphoblastic leukemia (20%) and acute myeloid leukemia (19%).
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190531 Source Type: research
This report is about a 45-year-old man with acute myeloid leukemia (AML), treated with chemotherapy and allogeneic bone marrow transplant (allo-BMT) in 2010. After allo-BMT the patient developed chronic graft-versus-host disease (cGvHD) and was treated with a corticosteroid and immunosuppressants. In 2018, he presented with a whitish lesion with a central ulcer in the left anterior portion of the tongue. An incisional biopsy revealed the histopathologic diagnosis of invasive squamous cell carcinoma (SCC), poorly differentiated.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190233 Source Type: research
Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterised by significant constitutional symptoms due to raised inflammatory cytokine levels, reactive bone marrow fibrosis and extramedullary haematopoiesis, with risk of transformation to acute myeloid leukaemia. It is an uncommon disease which can be primary or secondary to other myeloproliferative neoplasms [1]. Disease severity is assessed by a number of prognostic scoring systems [2-5]. For instance, based on Dynamic International Prognostic Scoring System (DIPSS) Plus risk category, the estimated median survival of patients with MF ranges from 16 months to 15 years [3,5].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Allogeneic hematopoietic cell transplantation (HCT) is recommended for patients with acute myelogenous leukemia (AML) with high cytogenetic or molecular risk. It is also the treatment of choice for patients with AML who fail to respond to conventional chemotherapy or who present with early disease relapse. It is also a therapeutic choice for patients with chronic myelogenous leukemia in the blast phase (CML-BP) who are refractory to second-generation tyrosine kinase inhibitors (TKIs). The intensity of the preparative regimen is usually tailored to the perceived capacity of the recipient to tolerate dose-intensive conditioning.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Allogeneic hematopoietic cell transplantation (HCT) is recommended for patients with acute myeloid leukemia (AML) with high cytogenetic or molecular risk. It is also the treatment of choice for AML patients who fail to respond to conventional chemotherapy or who present with early disease relapse. It is also a therapeutic choice for patients with chronic myeloid leukemia in the blast phase (CML-BP) who are refractory to second-generation tyrosine kinase inhibitors (TKI). The intensity of the preparative regimen is usually tailored to the perceived capacity of the recipient to tolerate dose-intense conditioning.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
By CHADI NABHAN, MD, MBA, FACP “The goal for me and for my clinical and research colleagues is to put ourselves out of a job as quickly as possible”. This is how Mikkael Sekeres ends his book “When Blood Breaks Down” based on true stories of patients with leukemia. I share Mikkael’s sentiments and have always stated that I’d be happy if I am out of a job caring for patients with cancer. To his and my disappointment, this wish is unlikely to ever come true, especially when dealing with leukemia. With almost 15 years of experience, Sekeres possesses a wealth of knowledge and pati...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Book Review Chadi Nabhan hematology Mikkael Sekeres Oncology When Blood Breaks Down Source Type: blogs
Michele Callea Acute myeloid leukemia (AML) is a heterogeneous group of diseases, whose classification is based on lineage-commitment and genetics. Although rare in childhood, it is the most common type of acute leukemia in adults, accounting for 80% of all cases in this age group. The prognosis of this disease remains poor (especially in childhood, as compared to acute lymphoblastic leukemia); however, overall survival has significantly improved over the past 30 years. The health of the oral cavity is a remarkable reflection of the systemic status of an individual. Identification of the signs and symptoms of oral le...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Authors: Chen X, Yu X, Wang DD, Xu H, Li Z Abstract Bone marrow transplants (BMT) are an established therapeutic strategy for patients with severe aplastic anemia, acute lymphoblastic leukemia, acute myeloid leukemia or chronic myeloid leukemia. However, the successful application of BMT is limited by graft-vs.-host disease (GVHD). Ciclosporin has been widely used for treating GVHD in pediatric patients who underwent BMT. The present study aimed to optimize the dosage of ciclosporin for safety and effectiveness based on population pharmacokinetics. A non-linear mixed-effects model was used to analyze the clinical d...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
our M Abstract Microtransplantation (MT) is based on injection of HLA-mismatched G-CSF mobilized hematopoietic stem cells, in combination with chemotherapy but without use of conditioning regimen nor immunosuppressive drugs. As a result, a transient microchimerism is induced without engraftment. Its efficacy relies both on host immune system stimulation (recipient versus tumor) and on a graft versus tumor effect. Data are scarce and concern mostly Asian patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (HR-MDS). In comparison to conventional treatment without MT, higher complete rem...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biotechnology | Bone Marrow Transplant | Health Management | Leukemia | Transplant Surgery | Transplants